Michael Miller, MD, FACC, FAHA, FNLA
Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Aruna Pradhan, MD, MPH
James A. Underberg, MD
Adopting the New Therapeutic “LineUp” t…
February 04, 2022
07:45 AM - 12:00 PM EST
Karol Watson, MD, PhD
Joseph Saseen, PharmD, BCPS, BCACP, CLS
Pam R. Taub, MD, FACC, FASPC
Charles P. Vega, MD
Adopting the New Therapeutic “Lineup” t…
March 19, 2022
07:45 AM - 12:00 PM PDT
April 04, 2022
05:15 PM - 09:30 PM CDT
Peter van der Meer, MD, PhD
Pieter Martens, MD, PhD
New Perspectives on the Management of HFrEF: Iron Deficiency and Cardiac Remodeling
New Perspectives on the Management of HFrEF: Iron Deficiency and Cardiac Remode…
Murray Epstein, MD
Gates B. Colbert, MD, FASN
Considerations When Using a Potassium Binder in Patients with CKD
Peter Rossing, DMSc, MD
Gerasimos S. Filippatos, MD, FESC, FHFA, FHFSA(h)
Matthew R. Weir, MD
New Insights into the Management of CKD in T2D: The Role of MRA Therapies
Peter Libby, MD
Lawrence A. Leiter, MD
Prof. Kausik Ray, MBChB, MD, MPhil
Panel Discussion on AHA Symposium: Clinical Rundown—3 Hot Topic Sessions on ASCVD Risk Reduction
Panel Discussion on AHA Symposium: Clinical Rundown—3 Hot Topic Sessions on ASC…
Mikhail Kosiborod, MD
Javed Butler, MD, MBA, MPH
Synergy of Guideline-Directed Medical Therapies in Heart Failure to Optimize Patient Outcomes
Synergy of Guideline-Directed Medical Therapies in Heart Failure to Optimize Pa…
Gregg C. Fonarow, MD
Andrew J. S. Coats, MD
Applying Key Updates from ESC/HFA to Managing Heart Failure
Keith C. Ferdinand, MD
Marco Metra, MD
Managing HK in HF: Navigating the Evolving Clinical Landscape
Ewa A. Jankowska, MD, PhD, FESC
Phil McEwan, PhD
Making the Case for Iron Replacement Therapy in HFrEF: Clinical and Pharmacoeconomic Impact
Making the Case for Iron Replacement Therapy in HFrEF: Clinical and Pharmacoeco…
Robert J. Chilton, DO
John R. Nelson, MD, FACC, FNLA, FASNC
Clinicians' Update on Omega-3s in ASCVD Risk Reduction
Ileana L. Piña, MD, MPH, FAHA, FACC
Giuseppe M.C. Rosano, MD, PhD, FESC, FHFA
From Guidelines to Practice: Key Updates From 2021 HFSA
Demystifying Continued Pharmacologic Therapy in HFrEF – Pivotal Opportunities to Improve Patient Outcomes
Demystifying Continued Pharmacologic Therapy in HFrEF – Pivotal Opportunities t…
Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC
A New Normal? COVID-19 and HF in Clinical Trials
Robert J. Mentz, MD, FHFSA, FACC, FAHA
A Clinical Guide to the Role of Iron in HF Pathophysiology
